Diagnostic and Therapeutic Approach to Acute Decompensated Heart Failure

American Journal of Medicine

Volumn 120, Issue 2, 2007, Pages 121-127

  Kapoor, John R ^a   Perazella, Mark A ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B type natriuretic peptide; Diuretics; Dobutamine; Heart failure; Nesiritide

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; DOBUTAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; INOTROPIC AGENT; LOOP DIURETIC AGENT; MILRINONE; NESIRITIDE; NITROPRUSSIDE SODIUM; VASODILATOR AGENT;

ACUTE HEART FAILURE; DIAGNOSTIC APPROACH ROUTE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG INDICATION; DYSPNEA; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEMODYNAMICS; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; METABOLIC ALKALOSIS; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; TACHYPHYLAXIS; UREMIA;

CARDIOTONIC AGENTS; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; VASODILATOR AGENTS;

EID: 33846569321     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.05.066     Document Type: Review

References (60)

1. Heart Disease and Stroke Statistics-2006 Update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) e85
2. Massie B.M., and Shah N.B. The heart failure epidemic. Curr Opin Cardiol 11 (1996) 221-226
3. O'Connell J.B., and Bristow M.R. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 13 (1994) S107-S112
4. CMS national 2001 in-patient discharge data base MEDPAR, DRG 427.
5. McCullough P.A., Nowak R.M., McCord J., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from breathing not properly (BNP) multinational study. Circulation 106 (2002) 416-422
6. Collins S.P., Lindsell C.J., Storrow A.B., et al. Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure. Ann Emerg Med 47 (2006) 13-18
7. Stevenson L.W., and Perloff J.K. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 261 (1989) 884-888
8. Garcia Rodriguez L.A., and Hernandez-Diaz S. Nonsteroidal anti-inflammatory drugs as a trigger of clinical heart failure. Epidemiology 14 (2003) 240-246
9. Drazner M.H., Rame J.E., Stevenson L.W., et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 345 (2001) 574-581
10. Chakko S., Woska D., Martinez H., et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med 90 (1991) 353-359
11. Ewy G.A. The abdominojugular test: technique and hemodynamic correlates. Ann Intern Med 109 (1988) 456-460
12. Nohira A., Tsang S.W., Fang J.C., et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41 (2003) 1797-1804
13. Ishii J., Nomura M., Nakamura Y., et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 89 (2002) 691-695
14. Horwich T.B., Patel J., MacLellan W.R., et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 108 (2003) 833-838
15. Silver M.A., Maisel A., Yancy C.W., et al. A clinical approach for the diagnostic, prognostic, screening, treatment, monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 10 (2004) 1-30
16. Lainchbury J.G., Campbell E., Frampton C.M., et al. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 42 (2003) 728-735
17. Gardner R.S., Ozalp F., Murday A.J., et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24 (2003) 1735-1743
18. Kazanegra R., Cheng V., Garcia A., et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Cardiol Fail 7 (2001) 21-29
19. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
20. Dao Q., Krishnaswamy P., Kazanegra R., et al. Utility of B-type natriuretic peptide (BNP) in the diagnosis of congestive heart failure in an urgent care setting. J Am Coll Cardiol 37 (2001) 379-385
21. Cheng V., Kazanagra R., Garcia A., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37 (2001) 386-391
22. Wu A.H., and Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 6 (2004) 355-358
23. Mueller C., Scholer A., Laule-Kilian K., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350 (2004) 647-654
24. Hsu H., Hickey R.F., Forbes A.R., et al. Morphine decreases peripheral vascular resistance and increases capacitance in man. Anesthesiology 50 (1979) 98
25. Peacock IV W.F., and Albert N.M. Observation uniti management of heart failure. Emerg Med Clin North Am 19 (2001) 209-232
26. Ellison D.H. Diuretic therapy and resistance in congestive heart failure. Cardiology 96 (2001) 132-143
27. Dormans T.P., van Meyel J.J., Gerlag P.G., et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 28 (1996) 376-382
28. Felker G.M., Leimberger J.D., Califf R.M., et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail 10 (2004) 460-466
29. Francis G.S., Siegel R.M., Goldsmith S.R., et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohormonal axis. Ann Intern Med 103 (1985) 1-6
30. Cooper H.A., Dries D.L., Davis C.E., et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100 (1999) 1311-1315
31. Costanzo M.R., Heywood J.T., DeMarco T., et al. Impact of renal insufficiency and chronic diuretic therapy on outcome and resource utilization in patients with acute decompensated heart failure. J Am Coll Cardiol 43 (2004) 180A
32. Enerman C.L., Marco T.D., Costanzo M.R., et al. Impact of intravenous diuretics on the outcomes of patients hospitalized with Acute Decompensated Heart Failure: insights from ADHERE Registry. J Card Fail 10 (2004) S116
33. Stevenson L.N. Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail 1 (1999) 251-257
34. Steimle A.E., Stevenson L.W., Chelimsky-Fallick C., et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation 96 (1997) 1165-1172
35. Cotter G., Metzkor E., Kaluski E., et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351 (1998) 389-393
36. Khot U.N., Novaro G.M., Popovic Z.B., et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 348 (2003) 1756-1763
37. Johnson W., Omland T., Hall C., et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 39 (2002) 1623-1629
38. Cohn J.N., Franciosa J.A., Francis G.S., et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med 306 (1982) 1129-1135
39. Mann T., Cohn P.F., Holman B.L., et al. Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Circulation 57 (1978) 732-738
40. Hobbs R.E., Mills R.M., and Young J.B. An update on nesiritide for treatment of decompensated heart failure. Expert Opin Investig Drugs 10 (2001) 935-942
41. Abraham W.T., Lowes B.D., Ferguson D.A., et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 4 (1998) 37-44
42. Mills R.M., Le Jemtel T.H., Horton D.P., et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 34 (1999) 155-162
43. Colucci W.S., Elkayam U., Horton D.P., et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 343 (2000) 246-253
44. Peacock W.F., and Emerman C.L. Safety and efficacy of nesiritide in the treatment of decompensated heart failure in observation patients: the PROACTION trial. J Am Coll Cardiol 41 (2003) 336A
45. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287 (2002) 1531-1540
46. Silver M.A., Horton D.P., Ghali J.K., et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 39 (2002) 798-803
47. Sackner-Bernstein J.D., Skopicki H.A., Aaronson K.D., et al. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
48. Sackner-Bernstein J.D., Kowalski M., Fox M., et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900-1905
49. Gheorghiade M., De Luca L., Fonarow G.C., et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 96 (2005) 11G-17G
50. Biddle T.L., Benotti J.R., Creager M.A., et al. Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. Am J Cardiol 59 (1987) 1345-1350
51. Colucci W.S., Wright R.F., Jaski B.E., et al. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. Circulation 73 (1986) III175-III183
52. Weinstein J., and Baim D.S. The effects of acute dobutamine administration on myocardial metabolism and energetics. Heart Fail 2 (1996) 110-116
53. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 38 (2001) 2101-2113
54. Lowes B.D., Tsvetkova T., Eichhorn E.J., et al. Milrinone versus docutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol 81 (2001) 141-149
55. Packer M., Carver J.R., Rodeheffer R.J., et al., The PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325 (1991) 1468-1475
56. Cuffe M.S., Califf R.M., Adams Jr. K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287 (2002) 1541-1547
57. Felker G.M., Benza R.L., Chandler A.B., et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41 (2003) 997-1003
58. Oliva F., Latini R., Politi A., et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J 138 (1999) 247-253
59. O'Conner C.M., Gattis W.A., Uretsky B.F., et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138 (1999) 78-86
60. Burger A.J., Horton D.P., LeJemtel T., et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 144 (2002) 1102-1108